Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that data from their Phase 1 clinical trial of ORX750, a novel orexin receptor 2 (OX2R) agonist, will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego.
The presentation will focus on Phase 1 clinical data of ORX750 in acutely sleep-deprived healthy participants. ORX750 is being developed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). The drug is currently being evaluated in an ongoing Phase 2a clinical trial called CRYSTAL-1.
The poster presentation will be delivered by Dr. Deborah Hartman, Global Scientific Head of the Orexin Program, on April 5, 2025, at 11:45 AM PT.
Centessa Pharmaceuticals (Nasdaq: CNTA) ha annunciato che i dati del loro studio clinico di Fase 1 su ORX750, un nuovo agonista del recettore dell'orexina 2 (OX2R), saranno presentati al Meeting Annuale dell'American Academy of Neurology (AAN) 2025 a San Diego.
La presentazione si concentrerà sui dati clinici di Fase 1 di ORX750 in partecipanti sani acutamente privati del sonno. ORX750 è in fase di sviluppo per il trattamento della narcolessia di tipo 1 (NT1), narcolessia di tipo 2 (NT2) e ipersomnia idiopatica (IH). Il farmaco è attualmente in fase di valutazione in uno studio clinico di Fase 2a chiamato CRYSTAL-1.
La presentazione del poster sarà tenuta dalla Dr.ssa Deborah Hartman, Responsabile Scientifico Globale del Programma Orexina, il 5 aprile 2025, alle 11:45 AM PT.
Centessa Pharmaceuticals (Nasdaq: CNTA) anunció que los datos de su ensayo clínico de Fase 1 sobre ORX750, un nuevo agonista del receptor de orexina 2 (OX2R), se presentarán en el Encuentro Anual de la Academia Americana de Neurología (AAN) 2025 en San Diego.
La presentación se centrará en los datos clínicos de Fase 1 de ORX750 en participantes sanos que han estado privados de sueño de manera aguda. ORX750 se está desarrollando para el tratamiento de narcolepsia tipo 1 (NT1), narcolepsia tipo 2 (NT2) e hipersomnia idiopática (IH). El fármaco se está evaluando actualmente en un ensayo clínico de Fase 2a llamado CRYSTAL-1.
La presentación del póster será realizada por la Dra. Deborah Hartman, Jefa Científica Global del Programa de Orexina, el 5 de abril de 2025, a las 11:45 AM PT.
Centessa Pharmaceuticals (Nasdaq: CNTA)는 새로운 오렉신 수용체 2 (OX2R) 작용제인 ORX750의 1상 임상 시험 데이터가 미국신경학회(AAN) 2025 연례 회의에서 샌디에고에서 발표될 것이라고 발표했습니다.
발표는 급성 수면 부족 상태의 건강한 참가자에서 ORX750의 1상 임상 데이터에 초점을 맞출 것입니다. ORX750은 제1형 나르콜렙시 (NT1), 제2형 나르콜렙시 (NT2) 및 특발성 과다수면증 (IH) 치료를 위해 개발되고 있습니다. 이 약물은 현재 CRYSTAL-1이라는 진행 중인 2a상 임상 시험에서 평가되고 있습니다.
포스터 발표는 오렉신 프로그램의 글로벌 과학 책임자인 Deborah Hartman 박사가 2025년 4월 5일 오전 11시 45분 PT에 진행할 예정입니다.
Centessa Pharmaceuticals (Nasdaq: CNTA) a annoncé que les données de leur essai clinique de Phase 1 sur ORX750, un nouvel agoniste du récepteur d'orexine 2 (OX2R), seront présentées lors de la Réunion Annuelle de l'American Academy of Neurology (AAN) 2025 à San Diego.
La présentation se concentrera sur les données cliniques de Phase 1 d'ORX750 chez des participants sains ayant subi une privation de sommeil aiguë. ORX750 est en cours de développement pour le traitement de la narcolepsie de type 1 (NT1), la narcolepsie de type 2 (NT2) et l'hypersomnie idiopathique (IH). Le médicament est actuellement évalué dans un essai clinique de Phase 2a appelé CRYSTAL-1.
La présentation du poster sera faite par Dr. Deborah Hartman, Responsable Scientifique Mondial du Programme Orexine, le 5 avril 2025 à 11h45 PT.
Centessa Pharmaceuticals (Nasdaq: CNTA) gab bekannt, dass Daten aus ihrer klinischen Phase-1-Studie zu ORX750, einem neuartigen Agonisten des Orexinrezeptors 2 (OX2R), auf dem Jahrestreffen der American Academy of Neurology (AAN) 2025 in San Diego präsentiert werden.
Die Präsentation wird sich auf die klinischen Daten der Phase 1 von ORX750 bei akut schlafentzugenen gesunden Teilnehmern konzentrieren. ORX750 wird zur Behandlung von Typ-1-Narkolepsie (NT1), Typ-2-Narkolepsie (NT2) und idiopathischer Hypersomnie (IH) entwickelt. Das Medikament wird derzeit in einer laufenden klinischen Phase-2a-Studie mit dem Namen CRYSTAL-1 bewertet.
Die Posterpräsentation wird von Dr. Deborah Hartman, Global Scientific Head des Orexin-Programms, am 5. April 2025 um 11:45 Uhr PT gehalten.
- Advanced to Phase 2a trials following Phase 1 completion
- Drug targets multiple sleep disorders (NT1, NT2, IH)
- None.
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.
Details of the poster presentation are as follows:
Title: Phase 1 Clinical Data with Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Participants
Abstract Number: 2277
Presenter: Deborah Hartman, PhD, Global Scientific Head, Orexin Program
Session Date and Time: Saturday, April 5, 2025, at 11:45 AM- 12:45 PM PT
Centessa’s booth number is 627. AAN abstracts are available on the conference website. Centessa’s poster will be available on the Centessa website at https://investors.centessa.com/events-presentations after the poster presentation concludes.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. We are developing potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), and excessive daytime sleepiness (EDS) in neurological, neurodegenerative, and psychiatric conditions. We also anticipate that our OX2R agonists may have utility in treating impaired attention, cognitive deficits, fatigue, and other symptoms. Our earlier stage pipeline is focused on immuno-oncology with our proprietary LockBody® technology platform.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
FAQ
What is the current development stage of Centessa's ORX750 drug for narcolepsy?
When will Centessa (CNTA) present the Phase 1 results for ORX750?
What conditions is Centessa's ORX750 targeting?
What type of drug is CNTA's ORX750?
